IEMN has joined Digital Surf's Mount Shasta technical cooperation programme with internationally reputed laboratories engaged in scientific research. One of the core areas of research at IEMN is the physics of nanostructures and quantum devices.
Intermolecular, Inc. has announced an ongoing project with King Abdullah University of Science and Technology (KAUST) for the enhancement of copper-indium-gallium-diselenide (CIGS) thin film photovoltaic manufacturing technology.
The Archetto 3 is a table-top system for interference lithography that is compact, simple to operate, and most importantly - with a price tag of ten of thousands instead of millions of dollars - low cost.
Applied Materials, Inc. today pushed the boundaries of interconnect technology, the pathways that connect the billions of transistors on a chip, with the announcement of its Applied Endura Amber PVD system.
XEI Scientific Inc, maker of the popular EVACTRON De-Contaminator Plasma Cleaning System for electron microscopes and other vacuum chambers, announce that they have begun shipments of the Evactron TEM Wand systems.
Intel commits approximately $1 billion to ASML's research and development programs to help accelerate deployment of new technologies for 450-millimeter wafers and extreme ultra-violet (EUV) lithography by as much as two years.
The innovative technology enables the creation of a nano-porous silicon dioxide film from a liquid precursor at room temperature and atmospheric pressure, making this technology compatible with all existing PV-module and solar glass manufacturing lines.
AIXTRON SE today announced the successful conclusion of the European Commission-funded "TECHNOTUBES" (Technology for Wafer-Scale Carbon Nanotubes) project, with a demonstration of its new automated growth equipment, BM 300T.
PDS Biotechnology Corporation announced that they have entered into an exclusive worldwide licensing agreement with Merck KGaA, Darmstadt, Germany, for use of PDS Biotechnology's novel Versamune nanotechnology platform in two of Merck's investigational antigen-specific cancer immunotherapies currently in pre-clinical development.